Výsledky vyhledávání - "Cristina B. Guzman"

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Autor: Cristina B. Guzman, Vincent Woo, S.J. Weisnagel, Xiaotian M. Zhang, Sheetal Pradhan, Gregg Gerety, George Tsoukas, Shuyu Zhang, Claude A. Piché, Elizabeth R. Seaquist, James R. Conway, Rémi Rabasa-Lhoret, Hélène Dulude, Dolorès Carballo

Publikováno v: Diabetes, Obesity & Metabolism

In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3c1c4f511ff0a612d555f5c7408b608
https://doi.org/10.1111/dom.13278

Zobrazit plný text záznamu

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Autor: Naga Chalasani, Thomas Hardy, Suman Duvvuru, Sudha S. Shankar, Anthony Akkari, Xiaotian Michelle Zhang, Sreekumar G. Pillai, Christof M. Kazda, Mark A. Deeg, Chakib Battioui, Pallav Bhatnagar, Wendra M. Foster, Cristina B. Guzman

Publikováno v: Hepatology Communications. 2:561-570

LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29415cd08f7a70309a76379dfe48093e
https://doi.org/10.1002/hep4.1171

Zobrazit plný text záznamu

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti

Autor: Xiaotian Michelle Zhang, Barry Reiner, Cristina B. Guzman, Sheetal Pradhan, Hélène Dulude, Shuyu Zhang, Claude A. Piché, Larry C. Deeb

Publikováno v: Pediatric Diabetes. 19:1007-1013

OBJECTIVE This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D). METHODS C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32fa5e7323e2faeda8460723b6d8b43d
https://doi.org/10.1111/pedi.12668

Zobrazit plný text záznamu

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Autor: Muhtarjan Osman, Manish R. Patel, Stephen D. Smith, Greg Coffey, Cristina B Guzman, Javier Munoz, Don A. Stevens, Tatyana Feldman, Brian T. Hess, Jaymes S Holland, Paul A. Hamlin, Sonali M. Smith

Publikováno v: Blood. 138:2423-2423

Background Relapsed/refractory follicular lymphoma (FL) is a challenging disease; novel therapeutics with different mechanisms of action are needed. Spleen tyrosine kinase (SYK) and Janus kinase (JAK) signaling pathways are activated in FL and appear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a54e4b03f1f1f2adf852dc9c163db0f7
https://doi.org/10.1182/blood-2021-148313

Zobrazit plný text záznamu

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Autor: Manish R. Patel, Sonali M. Smith, Cristina B Guzman, Jing C. Ye, Youn H. Kim, Tatyana Feldman, Muhtarjan Osman, Michael S. Khodadoust, Ryan A. Wilcox, Steven M. Horwitz, Paul A. Hamlin, Jaymes S Holland, Javier Munoz, Greg Coffey

Publikováno v: Blood. 138:622-622

Background Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of T-cell non-Hodgkin's lymphomas with poor prognosis that are often refractory to treatment. Spleen tyrosine kinase (SYK) and Janus kinase (JAK) signaling pathways are impo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa60bc2b179e090e14f440a4294b2f74
https://doi.org/10.1182/blood-2021-148352

Zobrazit plný text záznamu

Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial

Autor: Maryam Tafreshi, Emmanouil Rampakakis, Myriam Triest, Marianne Rufiange, Aziz A. Sadoune, Shuyu Zhang, Hélène Dulude, Claude A. Piché, Eric Sicard, Cristina B. Guzman, Michelle Xiaotian Zhang, Dolorès Carballo

Publikováno v: Diabetes, Obesity & Metabolism

Aims Nasal glucagon (NG) is a nasally-administered glucagon powder, absorbed through the nasal mucosa, designed for treatment of severe hypoglycaemia. This study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NG in otherwise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::347aacd2e1617d125dbc4d77cb20f4b2
https://doi.org/10.1111/dom.13134

Zobrazit plný text záznamu

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Autor: Parag Garhyan, Cristina B. Guzman, Thomas A. Hardy, Sudha S. Shankar, Rong Liu, Christof M. Kazda, Xiaotian M. Zhang, Sreekumar G. Pillai, Arie Regev, Naga Chalasani

Publikováno v: Diabetes, Obesity and Metabolism. 19:1521-1528

AIMS To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in hepatic fat and other safety variables related to the benefit-risk profile for chronic use in patients with type 2 diabe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4950eeb8ac1cecf876d262f95b5325d1
https://doi.org/10.1111/dom.12958

Zobrazit plný text záznamu

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

Autor: Parag Garhyan, Juan P. Frias, Xuewei Cui, Jihui Anne Yang, Irene Foga, Cory R. Heilmann, Cristina B. Guzman, Christof M. Kazda, Thomas Hardy

Publikováno v: Diabetes, Obesity and Metabolism. 19:1071-1077

Aims To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes. Materials and methods This 6-week, randomized, crossover study evaluated the effects of once-daily administration of LY2409021 20 mg vs those of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01196f9133282ba2f767798766465cbd
https://doi.org/10.1111/dom.12904

Zobrazit plný text záznamu

Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients With Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart

Autor: Cristina B. Guzman, Anuj Bhargava, James Thrasher, Tina M. Rees, Leonard C. Glass, Tao Wang

Publikováno v: Endocrine Practice. 21:247-257

This study provides clinical information regarding the use of insulin lispro versus insulin aspart in continuous subcutaneous insulin infusion (CSII) in adult patients with type 2 diabetes mellitus (T2D).After a 2-week lead-in period, 122 subjects tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fca2648dd90da514b8a593ecda2930
https://doi.org/10.4158/ep14242.or

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání